Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3093 |
|
Actual shortage: | 247 (8%) | |
Anticipated shortage: | 14 (0%) | |
Avoided shortage: | 9 (0%) | |
Resolved: | 2823 (91%) | |
Discontinuation Reports |
356 |
|
To be discontinued: | 22 (6%) | |
Discontinued: | 334 (94%) | |
Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
32 (11%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
MIRVALA 21 | 0.1500MG 0.0300MG | TABLET | Resolved | 2018-07-04 | 2018-07-12 | 54312 |
MIRVALA 21 | 0.0300MG 0.1500MG | TABLET | Resolved | 2022-10-21 | 2022-11-07 | 172355 |
MIRVALA 28 | 0.1500MG 0.0300MG | TABLET | Resolved | 2018-07-04 | 2018-07-12 | 54315 |
MIRVALA 28 | 0.1500MG 0.0300MG | TABLET | Resolved | 2019-01-30 | 2019-04-26 | 74028 |
MIRVALA 28 | 0.0300MG 0.1500MG | TABLET | Resolved | 2022-01-14 | 2022-01-18 | 152779 |
MYA | 3.00MG 0.02MG | TABLET | Resolved | 2017-03-11 | 2020-09-04 | 555 |
MYA | 0.02MG 3.00MG | TABLET | Resolved | 2023-05-26 | 2023-06-02 | 193206 |
MYA | 0.02MG 3.00MG | TABLET | Resolved | 2023-09-22 | 2023-10-06 | 204996 |
MYA | 0.02MG 3.00MG | TABLET | Resolved | 2023-12-15 | 2023-12-22 | 213568 |
MYA | 0.02MG 3.00MG | TABLET | Resolved | 2024-03-08 | 2024-03-15 | 221690 |
APO-ONDANSETRON | 4MG | SOLUTION | Resolved | 2017-03-13 | 2017-03-31 | 2019 |
APO-ONDANSETRON | 4MG | SOLUTION | Resolved | 2017-04-25 | 2018-03-14 | 7880 |
APO-ONDANSETRON | 4MG | SOLUTION | Resolved | 2018-12-19 | 2019-03-21 | 69959 |
APO-ONDANSETRON | 4MG | SOLUTION | Resolved | 2019-04-29 | 2019-08-22 | 82753 |
OVIMA 21 | 30MCG 150MCG | TABLET | Resolved | 2019-08-19 | 2019-09-05 | 91923 |
OVIMA 21 | 30MCG 150MCG | TABLET | Resolved | 2023-04-27 | 2023-05-06 | 190868 |
OVIMA 28 | 30MCG 150MCG | TABLET | Resolved | 2018-04-04 | 2018-05-03 | 44969 |
OVIMA 28 | 30MCG 150MCG | TABLET | Resolved | 2019-06-05 | 2019-09-23 | 85622 |
OVIMA 28 | 30MCG 150MCG | TABLET | Resolved | 2021-09-24 | 2021-11-15 | 146163 |
OVIMA 28 | 30MCG 150MCG | TABLET | Resolved | 2022-01-07 | 2022-02-07 | 152329 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
APO-CAPTO TAB 6.25MG | 6.25MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60339 |
APO-CARVEDILOL | 12.5MG | TABLET | To be discontinued | 2024-01-26 | 2024-04-01 | 217493 |
APO-CARVEDILOL | 3.125MG | TABLET | To be discontinued | 2024-01-26 | 2024-01-26 | 217496 |